Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing its lead oncology candidate, ONC010, toward future clinical studies, marking a significant step in the development of a novel approach to cancer treatment. ONC010 is a PNKP inhibitor designed to disrupt cancer cells’ DNA repair mechanisms, potentially overcoming treatment resistance that plagues many current therapies. The company recently completed kilogram-scale manufacturing of a key precursor used to produce ONC010’s active pharmaceutical ingredient, a crucial milestone that supports future formulation development, Good Manufacturing Practice (GMP) production, and clinical studies.
To bolster its development efforts, Onco-Innovations has signed a letter of intent with Nanosoft Polymers to advance polymer development, drug delivery optimization, and formulation work. Additionally, engagements with Nucro-Technics and Avance Clinical are supporting bioanalytical development and clinical and regulatory planning. These collaborations are part of the company’s broader strategy to build the manufacturing, formulation, and clinical infrastructure needed to advance ONC010 toward first-in-human studies.
The importance of this announcement lies in the potential of ONC010 to address a critical gap in oncology: resistance to existing treatments. By inhibiting PNKP, an enzyme involved in DNA repair, ONC010 may sensitize cancer cells to DNA-damaging agents, enhancing the efficacy of chemotherapy and radiation. This mechanism could offer new hope for patients with solid tumors that have become resistant to standard therapies. The progression to kilogram-scale manufacturing indicates that Onco-Innovations is moving beyond early-stage research into the practical challenges of drug production, a key step in translating scientific discoveries into clinical applications.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, with a mission to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology targeting solid tumors. For more information, visit the company’s website at https://oncoinnovations.com/.
As Onco-Innovations continues to build momentum, the successful completion of these preclinical steps will be critical for regulatory filings and eventual clinical trials. The company’s focus on the PNKP pathway represents a differentiated approach in the competitive oncology landscape, and its progress is being closely watched by investors and researchers alike. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.
